Danaher Reports Strong Q2 2026 Earnings and Raises Full Year Guidance

Details

The company also saw a 5.5% increase in revenues to $6.3 billion and an 8.0% increase in non-GAAP adjusted diluted net earnings per common share to $1.94. The strong performance led to an increase in the full year 2026 adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60. Additionally, Leica Biosystems, a Danaher subsidiary, announced its intention to acquire StatLab, a leading manufacturer of products across the core histology workflow.

Items reported

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.